Daiichi Sankyo Company, Limited

Mie University

Daiichi Sankyo Europe Gmbh

Toshiaki Ohtsuka

Toshinori Agatsuma

Tatsuji Matsuoka

Jun Hasegawa

Takeshi Takizawa

Yumi Matsui

Ichiro Watanabe

Atsushi Urano

Reimi Kawaida

Kensuke Nakamura

Ryuji Hashimoto

Hiroshi Shiku

Takako Kimura

Makiko Nakayama

Chigusa Yoshimura

Kento Tanaka

Naoya Shinozaki

Yasuki Kamai

Hiroko Yoshida

Junya Ichikawa

Kaori Nakahara

Yasushi Akahori

Shiho Kozuma

Sandra Miller

Ulrike Schubert

Junko Yamaguchi

Ayaka Yatsu

Shinji Furuzono

Akiko Oguni

Tohru Takahashi

Eisuke Tsuda

Keisuke Fukuchi

Yoshiharu Hiruma

Ingrid Schuster

Reimar Abraham

Dirk Ponsel

Philip Rodley

Tanja Lange

Robert Mühlbacher

Johannes Bange

Kathrin-Ladetzki Baehs

Shinko Hayashi

Steffen Runz

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

Human anti-FGFR4 antibody

The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Anti-DR5 antibodies, polynucleotides and methods

The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Anti-FGFR2 antibodies and methods of use thereof for treating cancer

Anti-FGFR2 antibodies and pharmaceutical compositions thereof

The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-MST1R antibodies and uses thereof

The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Anti-EPHA2 antibody

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Growing community of inventors

Tokyo, Japan

Toshiaki Ohtsuka